Nurse Practitioner in Belleville, KS Accepting Medicare
6 Nurse Practitioner nurses found. Showing 1 - 6
 Lauren Eitzmann, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 2337 G St Ste 100, Belleville, KS 66935 Phone: 785-527-2217 Fax: 785-527-5929 |
April Dawn Dickey, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 2626 Wesleyan Dr, Belleville, KS 66935 Phone: 785-527-5636 |
Lori Ann Rhine, ARNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 2337 G St Ste 100, Belleville, KS 66935 Phone: 785-527-2217 Fax: 785-527-5929 |
Briana Jensen, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 2337 G St, Belleville, KS 66935 Phone: 785-527-2217 Fax: 785-527-5929 |
Micki K Zenger, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2337 G St, Belleville, KS 66935 Phone: 785-527-2217 Fax: 785-527-5929 |
Mrs. Dianne K. Kramer, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2337 G St, Belleville, KS 66935 Phone: 785-527-2217 Fax: 785-527-5929 |
News Archive
Potential predictor of fast PD progression identified
The identification of genetic variants of the α-synuclein gene may help to predict which individuals with idiopathic Parkinson's disease are likely to experience fast progression of motor symptoms, according to findings from a US-based genetic study.
Scientists report novel gene therapy that halts vision loss in canine model of blinding disease
Scientists funded by the National Eye Institute report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.
Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.
Study finds obese people have higher lifetime medical costs despite shorter life expectancies
Obese U.S. residents in their 20s will incur lifetime medical bills between $5,340 and $29,460 more than their healthy-weight peers despite shorter life spans, according to a study published online in the journal Obesity, USA Today reports.
› Verified 7 days ago
Nurse Practitioner
Physician Assistant
Nurse Anesthetist - CR